Early detection to improve outcome in people with undiagnosed psoriatic arthritis: the PROMPT research programme including RCT
McHugh N. et al, (2025), Programme Grants for Applied Research, 1 - 56
Effect of a treatment strategy utilising Golimumab, Methotrexate and Corticosteroids versus Methotrexate and Corticosteroids in early, untreated Psoriatic Arthritis: results from the GOLMePsA investigator-initiated, single centre, double-blind, parallel-group, randomised controlled trial
COATES L. et al, (2025), The Lancet Rheumatology
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review
COATES L. et al, (2025), Advances in Therapy
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Study Nested Within an English and Welsh Audit Dataset
Charlton RA. et al, (2025), Annals of the Rheumatic Diseases
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.
Jethwa H. et al, (2025), Rheumatology (Oxford)
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44
Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study
James L. et al, (2025), The Journal of Rheumatology, jrheum.2024 - 1035.C1
Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study.
James L. et al, (2025), J Rheumatol
Association of clinical variables with methotrexate response in patients with psoriatic arthritis.
Kasiem FR. et al, (2025), Scand J Rheumatol, 1 - 8
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study.
López-Medina C. et al, (2025), Rheumatology (Oxford)
Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis.
McGagh D. et al, (2025), Lancet Rheumatol, 7, e55 - e63
Psoriatic Arthritis Priority Setting Partnership: patient and clinician informed considerations for future UK health service delivery
James L. et al, (2024), Rheumatology